InspireMD (NYSE:NSPR) and Carmell (NASDAQ:CTCX) Financial Analysis

Carmell (NASDAQ:CTCX) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Profitability

This table compares Carmell and InspireMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carmell	N/A	-217.50%	-50.22%
InspireMD	-413.96%	-69.42%	-57.68%

Institutional & Insider Ownership

24.2% of Carmell shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 29.0% of Carmell shares are owned by insiders. Comparatively, 29.7% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Carmell and InspireMD”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carmell	$32,839.00	571.40	-$15.44 million	N/A	N/A
InspireMD	$7.07 million	13.99	-$19.92 million	($0.83)	-2.86

Carmell has higher earnings, but lower revenue than InspireMD.

Analyst Ratings

This is a breakdown of current ratings for Carmell and InspireMD, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carmell	0	0	0	0	0.00
InspireMD	0	0	2	0	3.00

InspireMD has a consensus price target of $4.50, indicating a potential upside of 89.87%. Given InspireMD’s stronger consensus rating and higher probable upside, analysts clearly believe InspireMD is more favorable than Carmell.

Risk & Volatility

Carmell has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.

Summary

InspireMD beats Carmell on 8 of the 12 factors compared between the two stocks.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.